PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7+3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Amer M. Zaidan1, Amir T. Fathi1, Rhaya C. Issa2, Harry Ebrahimi3, Julie Mackey Aharon4, Daniel Corum5, Blake Tomkinson6, Tom Kostak7, Molly Leonardi7, Eunice S. Wang8

1Yale University, New Haven, CT; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA; 3The University of Texas MD Anderson Cancer Center, Houston, TX; 4Duke Cancer Institute, Durham, NC; 5Kura Oncology, Boston, MA; 6Roswell Park Comprehensive Cancer Center, Buffalo, NY

**BACKGROUND**

- Acute myeloid leukemia (AML) with nucleophosmin 1 (NPM1-m) mutations or lysine (K)-specific histone deacetylase 2-ERG (KMT2A-r) mutations is a high unmet need, as no Food and Drug Administration-approved targeted therapies exist today.

- There are approximately 6000 new cases of NPM1-m and 1000 to 2000 new cases of KMT2A-r each year in the United States.

- Adult patients harboring NPM1-m or KMT2A-r mutations have a poor prognosis, with a 5-year overall survival of about 50% and <20%, respectively.

- Ziftomenib is an investigational, potent, selective inhibitor that targets the menin-beta domain of the KMT2A-r cancer driver, which drives leukemogenesis in these subtypes (Figure 1).

**OBJECTIVES**

**Endpoints**

- **Primary**
  - Determine the safety and tolerability
  - Determine the preliminary clinical activity

- **Secondary**
  - Evaluate survival, disease control outcomes, markers for clinical activity
  - Prevalence and analysis of biological, cytogenetic, and molecular biomarkers in blood and BM collected at diagnosis, on-treatment, and at relapse
  - Characterization of biomarkers in family members and gene expression from blood and BM collected before and after administration of the veneto/azacitidine combination
  - Investigator assessed treatment responses per institutional guidelines

**INCLUSION CRITERIA**

- 18 years of age diagnosed with AML, with documented NPM1-m or KMT2A-r

**EXCLUSION CRITERIA**

- Diagnosis of promyelocytic leukemia or blast chronic myelomonocytic leukemia; history of BCR-ABL alteration

**TABLE 1. KEY OBJECTIVES AND ENDPOINTS**

**TABLE 2. KEY INCLUSION AND EXCLUSION CRITERIA**

**STUDY DESIGN**

**PHASE 1 STUDY OF ZIFTOMENIB COMBINATION CLINICAL TRIAL IN PATIENTS WITH NPM1-MUTANT OR KMT2A-REARRANGED T OR R R AML**

**REFERENCES**


**ACKNOWLEDGEMENTS**

Medical writing and editorial assistance were provided by Cynthia D. Gioiello, Scientific Information Services, LLC.

**DISCLOSURES**

- All authors had the opportunity to review and sign the final draft of this manuscript.
- The authors declared no potential conflicts of interest.
- No financial support or funding was received for this study.

- The study was supported by Kura Oncology, Inc.